Limited correlation between systemic biomarkers and neurocognitive performance before and during HIV treatment

Kevin Robertson, Alan Landay, Sachiko Miyahara, Alyssa Vecchio, Mary Clare Masters, Todd T Brown, Babafemi O. Taiwo

Research output: Contribution to journalArticle


The AIDS Clinical Trials Group (ACTG) study A5303 investigated the associations between neuropsychological performance (NP) and inflammatory biomarkers in HIV-infected participants. Fifteen NP tests were administered at baseline and week 48 to 233 ART naïve participants randomized to maraviroc- or tenofovir-containing ART. Neurocognition correlated modestly with markers of lymphocyte activation and inflammation pre-ART (percent CD38+/HLA-DR+(CD4+) (r = − 0.22, p = 0.02) and percent CD38+/HLA-DR+(CD8+) (r = − 0.25, p = 0.02)), and with some monocyte subsets during ART (r = 0.25, p = 0.02). Higher interleukin-6 and percent CD38+/HLA-DR+(CD8+) were independently associated with worse severity of HIV-associated neurocognitive disorders (HAND) (p = 0.04 and 0.01, respectively). More studies to identify HAND biomarkers are needed.

Original languageEnglish (US)
JournalJournal of neurovirology
Publication statusAccepted/In press - Jan 1 2019



  • Antiretroviral therapy
  • Biomarker
  • Inflammation
  • Monocytes
  • Neurocognitive performance

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology
  • Cellular and Molecular Neuroscience
  • Virology

Cite this